



## Quest Diagnostics to Present at Investor Conferences

March 29, 2001

TETERBORO, N.J., March 29 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to make presentations at two investor conferences during the next week.

Kenneth W. Freeman, Chairman and Chief Executive Officer, is scheduled to speak at the Banc of America Securities Healthcare Conference on Thursday, March 29, 2001 at the Four Seasons Hotel in Las Vegas, Nevada. The Quest Diagnostics presentation is scheduled to begin at approximately 1:30 p.m. Eastern Time. The public is invited to listen to a live webcast of the presentation on the Internet by visiting the following web address: [http://www.veracast.com/bas\\_healthcare2001/webcasts/id81305402.cfm](http://www.veracast.com/bas_healthcare2001/webcasts/id81305402.cfm). A replay of the webcast will be available for two weeks following the conference.

In addition, Robert A. Hagemann, Corporate Vice President and Chief Financial Officer, is scheduled to make a presentation at the Thomas Weisel Partners Healthcare Tailwinds 2001 Conference on Tuesday, April 3, 2001, at the Ritz Carlton Hotel in San Francisco, California. The Quest Diagnostics presentation is scheduled to begin at approximately 6:20 p.m. Eastern Time. The public is invited to listen to a live webcast of the presentation on the Internet by visiting the following web address: [http://www.veracast.com/twp\\_healthcare\\_2001/webcasts/44211125.cfm](http://www.veracast.com/twp_healthcare_2001/webcasts/44211125.cfm). A replay of the webcast will be available for 30 days following the conference.

Quest Diagnostics will release financial results for the first quarter ending March 31, 2001, after the close of the stock market on April 23, 2001. The company is currently in a "quiet" period and will discuss results for the first quarter during a conference call on April 24 at 8:00 a.m. Eastern Time. To hear a simulcast of the call over the Internet, or a replay, registered analysts may access StreetEvents at: <http://www.streetevents.com> and all others may access the Quest Diagnostics website at: <http://www.questdiagnostics.com>. In addition, a replay of the call will also be available from 10 a.m. on April 24 through 5 p.m. on April 26 to investors in the U.S. by dialing 800-342-8825. Investors outside the U.S. may dial 402-220-9674. No password is required for either number.

Quest Diagnostics is the nation's leading provider of diagnostic testing, information and services with \$3.4 billion in annual revenues. The company's diagnostic testing yields information that enables health care professionals and consumers to make better decisions to improve health. Quest Diagnostics offers patients and physicians the broadest access to diagnostic testing services through its national network of approximately 30 full-service laboratories, 150 rapid response laboratories and more than 1,300 patient service centers, where specimens are collected. Quest Diagnostics is the leading provider of esoteric testing, including gene-based testing, and is the leader in routine medical testing, drugs of abuse testing, and anatomic pathology testing. Through partnerships with pharmaceutical, biotechnology and information technology companies, Quest Diagnostics provides support to help speed the development of health care insights and new therapeutics. Additional company information can be found on the Internet at: <http://www.questdiagnostics.com>.

The statements in this press release which are not historical facts or information may be forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the outcome to be materially different. Certain of these risks and uncertainties are listed in the Quest Diagnostics Incorporated 1999 Form 10-K and subsequent filings. SOURCE Quest Diagnostics Incorporated

CONTACT: Media - Mary Samuels, 201-393-5700, or Investors - Cathy Doherty, 201-393-5030, both for Quest Diagnostics Incorporated/